AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29561066 — intervention group
Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase) 0.25 mg/kg ×1
Number of subjects: 8
Study 29561066 — intervention group
Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase) 0.25 mg/kg ×2
Number of subjects: 8
Study 29561066 — intervention group
Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase)
Number of subjects: 8
Study 29561219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute reperfusion therapies including thrombectomy and thrombolysis in the acute phase
Number of subjects: 0
Study 29561219 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics including rate of thrombolysis in acute stroke
Number of subjects: 0
Study 29561219 — intervention group
Group type: COMPARATOR
Intervention: Key performance indicators in secondary prevention
Number of subjects: 0
Study 29561296 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (≤4 ml 10 PFU/ml; administered on day 1 and every 2 weeks thereafter)
Number of subjects: 2
Study 29561296 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 2
Study 29562804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1125
Study 29562804 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 1125
Study 29562804 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 1125
Study 29562855 — intervention group
Group type: EXPERIMENTAL
Intervention: RectroNectin-activated cytokine-induced killer (R-CIK) cell immunotherapy
Number of subjects: 125
Study 29562855 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy only)
Number of subjects: 125
Study 29562895 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM classified by the 2013 WHO criteria
Number of subjects: 1092
Study 29562895 — intervention group
Group type: COMPARATOR
Intervention: Women without GDM by both criteria
Number of subjects: 1092
Study 29562937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent renal replacement therapy (IRRT)
Number of subjects: 0
Study 29562937 — intervention group
Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0
Study 29563196 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 0
Study 29563634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 131
Study 29563634 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 131
Study 29563837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictive model using random forest, genetic algorithms, and classification and regression trees.
Number of subjects: 1945
Study 29563837 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk categorization using the decision tree model.
Number of subjects: 1945
Study 29563837 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off point of estimated risk.
Number of subjects: 1945
Study 29563871 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and Bupropion combination treatment
Number of subjects: 0
Study 29563871 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29564045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone at a starting dose of 10/5 mg/day (maximum 80/40 mg/day) for 8 weeks
Number of subjects: 209
Study 29564045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone
Number of subjects: 209
Study 29564161 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with microencapsulated pirimiphos-methyl (Actellic 300 CS) once a year for 2 years, in addition to long-lasting insecticide-treated nets (LLINs).
Number of subjects: 1548
Study 29564161 — intervention group
Group type: COMPARATOR
Intervention: Long-lasting insecticide-treated nets (LLINs) only.
Number of subjects: 1548
Study 29564161 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS intervention (pirimiphos-methyl) and LLINs.
Number of subjects: 1548
Study 29564726 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilatory support with lower maximum airway pressure
Number of subjects: 935
Study 29564726 — intervention group
Group type: COMPARATOR
Intervention: Patients who died
Number of subjects: 935
Study 29564996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group from clinical trials NCT00241644 and NCT00362648)
Number of subjects: 0
Study 29564996 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antibiotic use
Number of subjects: 0
Study 29565018 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerable patients (Clinical Frailty Score 3 or 4)
Number of subjects: 308
Study 29565018 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients (Clinical Frailty Score 5 or 6)
Number of subjects: 308
Study 29565018 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall frailty (including vulnerable and frail classifications)
Number of subjects: 308
Study 29565018 — intervention group
Group type: COMPARATOR
Intervention: Geriatric consultation (only 10 patients received this)
Number of subjects: 308
Study 29565190 — intervention group
Group type: EXPERIMENTAL
Intervention: GenPs prevalence at the time of enrollment in two prospective randomized phase 3b trials (NCT02561806 and NCT02634801)
Number of subjects: 0
Study 29565190 — intervention group
Group type: EXPERIMENTAL
Intervention: GenPs prevalence reported in literature
Number of subjects: 0
Study 29565424 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 L rhGAA
Number of subjects: 113
Study 29565961 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fluoroscopy (RTF)
Number of subjects: 128
Study 29565961 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 128
Study 29566106 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, 10 mg/kg, by 1-hour intravenous infusion every 2 weeks until disease progression or unacceptable toxic effects.
Number of subjects: 39
Study 29566106 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab treatment
Number of subjects: 39
Study 29566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Red and processed meat intake (10 g/d)
Number of subjects: 2586
Study 29566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal intake (50 g/d)
Number of subjects: 2586
Study 29566186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake (10 g/d)
Number of subjects: 2586
Study 29566185 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fats from plant sources (MUFA-P)
Number of subjects: 93484
Study 29566185 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fats from animal sources (MUFA-A)
Number of subjects: 93484
Study 29566185 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of the sum of MUFA-As and SFAs (5% of energy) with MUFA-Ps
Number of subjects: 93484
Study 29566190 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier introduction of complementary food (<4 mo old)
Number of subjects: 36481
Study 29566190 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake from dairy products (per 5 g/d)
Number of subjects: 36481
Study 29566190 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake from meat and fish (per 2 g/d)
Number of subjects: 36481
Study 29566195 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum formate concentrations
Number of subjects: 1701
Study 29566195 — intervention group
Group type: COMPARATOR
Intervention: Gender (women)
Number of subjects: 1701
Study 29566195 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype of MTHFR 677C→T (rs1801133) polymorphism
Number of subjects: 1701
Study 29566195 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential metabolic precursors (serine, methionine, tryptophan, choline)
Number of subjects: 1701
Study 29566195 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum folate
Number of subjects: 1701
Study 29566195 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin B-12
Number of subjects: 1701
Study 29566201 — intervention group
Group type: COMPARATOR
Intervention: Formal employment
Number of subjects: 184548
Study 29566201 — intervention group
Group type: COMPARATOR
Intervention: Informal employment
Number of subjects: 184548
Study 29566201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonemployment
Number of subjects: 184548
Study 29566246 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (300 mg/120 mg) for 8 weeks in noncirrhotic patients and 12 weeks in cirrhotic patients.
Number of subjects: 153
Study 29566654 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-oculography (VOG) with alternate cover
Number of subjects: 34
Study 29566654 — intervention group
Group type: COMPARATOR
Intervention: Alternate prism cover test (APCT)
Number of subjects: 34
Study 29566654 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-oculography (VOG)
Number of subjects: 34
Study 29566656 — intervention group
Group type: EXPERIMENTAL
Intervention: blended cognitive behavioral therapy (b-CBT) consisting of three face-to-face sessions and eight online sessions
Number of subjects: 156
Study 29566656 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 156
Study 29566673 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength measurement implementation training for nursing staff
Number of subjects: 155
Study 29566673 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength measurement
Number of subjects: 155
Study 29566673 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of grip strength measurement
Number of subjects: 155
Study 29566673 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and implementation of grip strength measurement
Number of subjects: 155
Study 29566688 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of five seminars over 6 months for staff and managers in nursing homes.
Number of subjects: 20
Study 29566688 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 20
Study 29566698 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health intervention program from infancy to age 5 years.
Number of subjects: 119
Study 29566698 — intervention group
Group type: COMPARATOR
Intervention: Control group of children with CHD who did not receive the program, born 2005-2007.
Number of subjects: 119
Study 29566699 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative analysis of GWAS and gene expression
Number of subjects: 0
Study 29566732 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-level stakeholder engagement measures including local meetings with community leaders and engagement with family members of prospective trial participants.
Number of subjects: 0
Study 29566730 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened training in depression components of PC101 and clinical communication skills for nurse-led chronic care, with a facility-based behavioural health counsellor providing structured manualised counselling for depression.
Number of subjects: 1000
Study 29566730 — intervention group
Group type: COMPARATOR
Intervention: Standard training in Primary Care 101 (PC101) for integrated chronic care including guidelines for hypertension and depression care.
Number of subjects: 1000
Study 29566744 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Exercise and ACT programme
Number of subjects: 160
Study 29566744 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise classes (Control)
Number of subjects: 160
Study 29566762 — intervention group
Group type: EXPERIMENTAL
Intervention: CyberKnife accelerated partial breast irradiation (CK-APBI) with 30 Gy in five fractions, treatment time approximately 60 min (range 35 to 120 min).
Number of subjects: 20
Study 29566766 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized tele-rehabilitation platform (GNPT)
Number of subjects: 0
Study 29566812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 287
Study 29566820 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm-born individuals
Number of subjects: 101
Study 29567071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil-based chemotherapy after D2 gastrectomy (n=193)
Number of subjects: 932
Study 29567071 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (n=114)
Number of subjects: 932
Study 29567071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus surgery (n=323)
Number of subjects: 932
Study 29567071 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (n=302)
Number of subjects: 932
Study 29567071 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive single patient classifier (based on GZMB, WARS, and CDX1)
Number of subjects: 932
Study 29567071 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive single patient classifier (based on GZMB, WARS, and SFRP4)
Number of subjects: 932
Study 29567461 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP-001
Number of subjects: 0
Study 29567632 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 20
Study 29567667 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for insomnia
Number of subjects: 0
Study 29567774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide, dosage and duration not available
Number of subjects: 0
Study 29567781 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel regimen for relapsed/refractory adult acute myeloid leukemia
Number of subjects: 0
Study 29567784 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment until focal lesion signal suppression
Number of subjects: 596
Study 29567784 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment post day 7
Number of subjects: 596
Study 29567784 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of more than 3 focal lesions at presentation
Number of subjects: 596
Study 29567785 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA polymerase ν gene expression
Number of subjects: 99
Study 29567798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 0
Study 29567858 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum bicarbonate levels
Number of subjects: 2853
Study 29568374 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate receptor-targeted intraoperative molecular imaging (FR-IMI) with OTL38
Number of subjects: 12
Study 29568762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with epilepsy
Number of subjects: 100
Study 29568762 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 29569246 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T3-J2 feeder cell culture with Y-27632 (ROCK inhibitor) in conditional reprograming conditions (CRC)
Number of subjects: 12
Study 29569246 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12
Study 29569311 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal targeted prostate biopsy
Number of subjects: 32
Study 29569385 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste dysfunction assessment using validated taste strips for sweet, sour, salty, and bitter; olfactory testing using the Sniffin' Sticks Test; endoscopic evaluation using Lund-Kennedy and OCES systems.
Number of subjects: 68
Study 29569385 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) surveys related to taste, smell, overall sinus-specific QOL, and depression.
Number of subjects: 68
Study 29570248 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term overfeeding (OF)
Number of subjects: 21
Study 29570897 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad definition of on-label prescribing
Number of subjects: 4519
Study 29570897 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive definition excluding patients with conditions for which dabigatran is not indicated
Number of subjects: 4519
Study 29570971 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 and escitalopram
Number of subjects: 64
Study 29570971 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 and fluoxetine
Number of subjects: 64
Study 29570971 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 and sertraline
Number of subjects: 64
Study 29570971 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 and O-desmethylvenlafaxine
Number of subjects: 64
Study 29570971 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2B6 and sertraline
Number of subjects: 64
Study 29571565 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic influences on food timing
Number of subjects: 106
Study 29571565 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of breakfast
Number of subjects: 106
Study 29571565 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of lunch
Number of subjects: 106
Study 29571565 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of dinner
Number of subjects: 106
Study 29571565 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake time
Number of subjects: 106
Study 29571565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime
Number of subjects: 106
Study 29571565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate analyses of food timing and bedtime/chronotype
Number of subjects: 106
Study 29571601 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased proportion of circulating CD4 T-lymphocytes
Number of subjects: 0
Study 29571602 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwood procedure
Number of subjects: 461
Study 29571854 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg three times a week
Number of subjects: 150
Study 29571854 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg daily
Number of subjects: 150
Study 29571946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice per day)
Number of subjects: 56
Study 29572283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar volume loss
Number of subjects: 70
Study 29572391 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of donor-derived CD8
Number of subjects: 0
Study 29572391 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29572709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg/m for at least 6 months
Number of subjects: 19
Study 29572709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with everolimus 10 mg/d
Number of subjects: 19
Study 29572709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide alone and with everolimus
Number of subjects: 19
Study 29573215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671
Study 29573215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study 29573876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 175
Study 29573876 — intervention group
Group type: COMPARATOR
Intervention: Td
Number of subjects: 175
Study 29573889 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (30 g/day) for 10 weeks
Number of subjects: 40
Study 29573889 — intervention group
Group type: COMPARATOR
Intervention: Normal diet without broccoli sprouts for 10 weeks
Number of subjects: 40
Study 29574070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/d)
Number of subjects: 12
Study 29574465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV test
Number of subjects: 334
Study 29574497 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD (albuminuria ≥ 30 mg/day)
Number of subjects: 15773
Study 29574497 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged < 55 years with worse albuminuria or eGFR category
Number of subjects: 15773
Study 29574497 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged ≥ 75 years with albuminuria < 10 mg/day
Number of subjects: 15773
Study 29574497 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher albuminuria and lower eGFR (even in normal range)
Number of subjects: 15773
Study 29574622 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/week MTX + adalimumab
Number of subjects: 0
Study 29574622 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/week MTX + adalimumab
Number of subjects: 0
Study 29574622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab initiation
Number of subjects: 0
Study 29574635 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (LM50)
Number of subjects: 156
Study 29574635 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro mix 25 (LM25)
Number of subjects: 156
Study 29574916 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation interventions targeting functional capabilities and home environment
Number of subjects: 180
Study 29574916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PICU functional status and capabilities
Number of subjects: 180
Study 29574916 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environmental support
Number of subjects: 180
Study 29574916 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 180
Study 29575698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (3,000 m, n=12)
Number of subjects: 23
Study 29575698 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training (n=11)
Number of subjects: 23
Study 29575771 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer (C-WL)
Number of subjects: 12
Study 29575771 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 29576119 — intervention group
Group type: EXPERIMENTAL
Intervention: US patients
Number of subjects: 14334
Study 29576119 — intervention group
Group type: COMPARATOR
Intervention: International patients
Number of subjects: 14334
Study 29576127 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP-step method (PSM)
Number of subjects: 24
Study 29576127 — intervention group
Group type: COMPARATOR
Intervention: Conventional method using oesophageal pressure (PES) measurements
Number of subjects: 24
Study 29576258 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29576341 — intervention group
Group type: EXPERIMENTAL
Intervention: Human bone marrow-derived stem cells (BMDSCs) infusion
Number of subjects: 0